PGN-EDODM1
Phase 2Small molecule
PGN-EDODM1 is one of 9 small molecule programs targeting Myotonic Dystrophy Type 1. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Myotonic Dystrophy Type 1
#DrugCompanyPhaseTrials
1Mexitil
Boehringer IngelheimPhase 3
Ritalin
NovartisPhase 2
Wakix
HHarmony Biosciences Management, Inc.
Phase 2
DYNE-101
DDyne Therapeutics
Phase 3
Ranexa
MMenarini International Operations Luxembourg SA
Phase 1
Rhigf-I/rhigfbp-3
TakedaPhase 2
AOC 1020
AAvidity Biosciences, Inc.
Phase 2
Sefaxersen (RO7434656)
RochePhase 2
PGN-EDODM1
PPepGen Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myotonic Dystrophy Type 13 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PGN-EDODM1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPepGen Inc